Christiane Pott

A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling

Michael Hummel, Stefan Bentink, Hilmar Berger et al. · New England Journal of Medicine · 2006 · 1K citations · Full text

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel et al. · The Lancet Oncology · 2015 · 608 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr et al. · Blood · 2005 · 534 citations

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling et al. · Blood · 2006 · 464 citations · Full text

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Constantine S. Tam, Mary Ann Anderson, Christiane Pott et al. · New England Journal of Medicine · 2018 · 417 citations